Quarterly ResultMay 7, 2026, 04:19 PM
Personalis Q1 Revenue Down to $15.5M; Net Loss $(30.0)M
AI Summary
Personalis, Inc. reported a significant widening of its net loss and a decrease in revenue for the first quarter of 2026 compared to the same period in 2025. Revenue fell to $15.5 million from $20.6 million, while the net loss increased to $30.0 million from $15.8 million. The company continues to invest heavily in research and development and sales and marketing efforts, expecting to incur additional losses for the foreseeable future.
Key Highlights
- Net loss for Q1 2026 was $(30.0) million, compared to $(15.8) million in Q1 2025.
- Revenue for Q1 2026 decreased to $15.5 million from $20.6 million in Q1 2025.
- Net loss per share was $(0.29) for Q1 2026, up from $(0.18) in Q1 2025.
- Cash and cash equivalents decreased to $73.6 million as of March 31, 2026, from $124.2 million at Dec 31, 2025.
- Pharma testing services revenue decreased to $10.7 million in Q1 2026 from $13.6 million in Q1 2025.
- Enterprise sales revenue dropped to $0.4 million in Q1 2026 from $2.5 million in Q1 2025.
- Clinical diagnostic revenue increased to $1.4 million in Q1 2026 from $0.3 million in Q1 2025.
- Net cash used in operating activities was $(22.5) million in Q1 2026, compared to $(18.0) million in Q1 2025.